13个欧洲国家的国家免疫技术咨询小组在疫苗建议决策过程中的作用。

IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES
Domenico Martinelli, Filippo Quattrone, Francesca Fortunato, Elisa Di Maggio, Antonietta Filia, Maria Cristina Rota, Pier Luigi Lopalco, Rosa Prato
{"title":"13个欧洲国家的国家免疫技术咨询小组在疫苗建议决策过程中的作用。","authors":"Domenico Martinelli, Filippo Quattrone, Francesca Fortunato, Elisa Di Maggio, Antonietta Filia, Maria Cristina Rota, Pier Luigi Lopalco, Rosa Prato","doi":"10.2807/1560-7917.ES.2023.28.43.2300131","DOIUrl":null,"url":null,"abstract":"<p><p>In Europe, National Immunisation Technical Advisory Groups (NITAGs) were established in most countries to promote evidence-informed decision-making in introducing new or improved vaccines or changing recommendations for existing ones. Still, the role, activities and outcomes of NITAGs have not been optimally implemented across Europe. Within the European Joint Action on Vaccination (EU-JAV), we conducted a survey to collect information on decision-making process including the main criteria for the introduction of new vaccines or changes to recommendations on their use. Between December 2021 and January 2022, 13 of the 28 European countries invited participated in an online survey. The criteria ranked as most relevant were disease burden and availability of financial resources. Only one country specified that the NITAG recommendations were binding for the government or the health authority. Vaccinations more often reported for introduction or recommendation changes were those against herpes zoster, influenza, human papillomavirus infection, pneumococcal and meningococcal disease. The planned changes will mainly address children and adolescents (2-18 years) and adults (≥ 45-65 years). Our findings show potential overlaps in the activities of NITAGs between countries; and therefore, collaboration between NITAGs may lead to optimisation of the workload and better use of resources.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"28 43","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604541/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of the National Immunisation Technical Advisory Groups in 13 European countries in the decision-making process on vaccine recommendations.\",\"authors\":\"Domenico Martinelli, Filippo Quattrone, Francesca Fortunato, Elisa Di Maggio, Antonietta Filia, Maria Cristina Rota, Pier Luigi Lopalco, Rosa Prato\",\"doi\":\"10.2807/1560-7917.ES.2023.28.43.2300131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In Europe, National Immunisation Technical Advisory Groups (NITAGs) were established in most countries to promote evidence-informed decision-making in introducing new or improved vaccines or changing recommendations for existing ones. Still, the role, activities and outcomes of NITAGs have not been optimally implemented across Europe. Within the European Joint Action on Vaccination (EU-JAV), we conducted a survey to collect information on decision-making process including the main criteria for the introduction of new vaccines or changes to recommendations on their use. Between December 2021 and January 2022, 13 of the 28 European countries invited participated in an online survey. The criteria ranked as most relevant were disease burden and availability of financial resources. Only one country specified that the NITAG recommendations were binding for the government or the health authority. Vaccinations more often reported for introduction or recommendation changes were those against herpes zoster, influenza, human papillomavirus infection, pneumococcal and meningococcal disease. The planned changes will mainly address children and adolescents (2-18 years) and adults (≥ 45-65 years). Our findings show potential overlaps in the activities of NITAGs between countries; and therefore, collaboration between NITAGs may lead to optimisation of the workload and better use of resources.</p>\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"28 43\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604541/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2023.28.43.2300131\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2023.28.43.2300131","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

在欧洲,大多数国家都成立了国家免疫技术咨询小组,以促进在引入新的或改进的疫苗或改变现有疫苗的建议时做出基于证据的决策。尽管如此,NITAG的作用、活动和成果并没有在整个欧洲得到最佳实施。在欧洲疫苗接种联合行动(EU-JAV)范围内,我们进行了一项调查,以收集决策过程的信息,包括引入新疫苗的主要标准或对其使用建议的更改。2021年12月至2022年1月,受邀的28个欧洲国家中有13个参加了一项在线调查。被列为最相关的标准是疾病负担和财政资源的可用性。只有一个国家明确表示,NITAG的建议对政府或卫生当局具有约束力。据报道,引入或建议更改的疫苗是针对带状疱疹、流感、人乳头瘤病毒感染、肺炎球菌和脑膜炎球菌疾病的疫苗。计划中的变化将主要针对儿童和青少年(2-18 年)和成人(≥ 45-65 年)。我们的研究结果表明,国家间NITAG的活动可能存在重叠;因此,NITAG之间的协作可以优化工作负载并更好地利用资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Role of the National Immunisation Technical Advisory Groups in 13 European countries in the decision-making process on vaccine recommendations.

Role of the National Immunisation Technical Advisory Groups in 13 European countries in the decision-making process on vaccine recommendations.

In Europe, National Immunisation Technical Advisory Groups (NITAGs) were established in most countries to promote evidence-informed decision-making in introducing new or improved vaccines or changing recommendations for existing ones. Still, the role, activities and outcomes of NITAGs have not been optimally implemented across Europe. Within the European Joint Action on Vaccination (EU-JAV), we conducted a survey to collect information on decision-making process including the main criteria for the introduction of new vaccines or changes to recommendations on their use. Between December 2021 and January 2022, 13 of the 28 European countries invited participated in an online survey. The criteria ranked as most relevant were disease burden and availability of financial resources. Only one country specified that the NITAG recommendations were binding for the government or the health authority. Vaccinations more often reported for introduction or recommendation changes were those against herpes zoster, influenza, human papillomavirus infection, pneumococcal and meningococcal disease. The planned changes will mainly address children and adolescents (2-18 years) and adults (≥ 45-65 years). Our findings show potential overlaps in the activities of NITAGs between countries; and therefore, collaboration between NITAGs may lead to optimisation of the workload and better use of resources.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Eurosurveillance
Eurosurveillance INFECTIOUS DISEASES-
CiteScore
32.70
自引率
2.10%
发文量
430
审稿时长
3-8 weeks
期刊介绍: Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信